On March 10, 2011 Biothera reported that it has acquired the anti-cancer monoclonal antibody AS1402 from Antisoma for undisclosed terms (Press release, Cancer Research Technology, MAR 10, 2011, View Source [SID1234523525]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

AS1402 is a monoclonal antibody that targets an aberrant form of the cell-surface protein MUC1 that is widely expressed in many types of cancer. Prior to the acquisition, the experimental drug had been in Phase 2 development. AS1402 was originally developed by CRT.

To find out more, visit the Biothera website.